[1]秦君璞,张帝开*.高龄夫妇再生育后的避孕新关注[J].中国计划生育和妇产科,2017,(6):10-13.
点击复制

高龄夫妇再生育后的避孕新关注
分享到:

《中国计划生育和妇产科》[ISSN:1674-4020/CN:51-1708/R]

卷:
期数:
2017年6期
页码:
10-13
栏目:
专题
出版日期:
2017-06-25

文章信息/Info

作者:
秦君璞张帝开*
中山大学附属第六医院妇科
分类号:
R 715.2

参考文献/References:

[1]覃民,李伯华.避孕方法知情选择与已婚育龄妇女避孕选择变化 [J].中国计划生育学杂志,2009,17(5):281-284. [2]武向飞,黎荔,龙茜,等.已婚女性人工流产术后放置宫内节育器的影响因素分析 [J].中国计划生育学杂志,2016,24(4):246-251. [3]周颖,李玉艳,赵洪鑫.中国三城市已婚流动人口避孕方法使用构成分析 [J].国际生殖健康/ 计划生育杂志,2012,3 (31):186-202. [4]李玉艳,武俊青.我国口服避孕药的使用现状和对策 [J].中国计划生育学杂志,2016,24(8):508-511. [5]PETERSEN K B, HOFFMANN E, LARSEN C R, et al. Cesarean scar pregnancy: a systematic review of treatment studies [J]. Fertility and Sterility, 2016, 105(4): 958-967. [6]HELLERSTEIN S, FELDMAN S, DUAN T. China's 50% caesarean delivery rate: is it too high? [J]. BJOG-An International Journal of Obstetrics and Gynaecology, 2015, 122(2): 160-164. [7]TIMOR-TRITSCH I E, MONTEAGUDO A, SANTOS R, et al. The diagnosis, treatment, and follow-up of cesarean scar pregnancy [J]. American Journal of Obstetrics and Gynecology, 2012, 207(1): 44.e1-44.13. [8]冯旺琴,李长东,陈素文.多环节干预减少重复剖宫产瘢痕妊娠 [J].中国计划生育学杂志,2016,24(3):207-209. [9]TRUSSELL J, HASSAN F, LOWIN J, et al. Achieving cost-neutrality with long-acting reversible contraceptive methods [J]. Contraception, 2015, 91(1): 49-56. [10]WHALEY N S, BURKE A E. Intrauterine contraception [J]. Women's Health (London, England), 2015, 11(6): 759-767. [11]胡静(摘译),吴尚纯(审校).无支架含铜宫内节育器(吉妮)与TCu 380 A宫内节育器:多中心随机比较性研究8年结果 [J].国际生殖健康/计划生育杂志,2013,4(4):273-274. [12]徐珉.多次或短期内重复人工流产后即时放置吉妮致美宫内节育器的临床效果观察 [J].中国计划生育学杂志,2013,21(10):690-691, 717. [13]JATLAOUI T C, RILEY H E, CURTIS K M. The safety of intrauterine devices among young women: a systematic review [J]. Contraception, 2017, 95(1): 17-39. [14]侯自红,吴尚纯,顾向应.产后和流产后使用长效可逆避孕方法的技术指南 [J].国际生殖健康/计划生育杂志,2013,4(4):267-268, 289. [15]WILDEMEERSCH D, JANSSENS D, ANDRADE A. The femilis LNG-IUS: contraceptive performance-an interim analysis [J]. The European Journal of Contraception & Reproductive Health Care: the Official Journal of the European Society of Contraception, 2009, 14(2): 103-110. [16]Dirk Wildemeersch, Norman D Goldstuck, Geert Jackers.Results of a 5-year contraceptive trial in parous and nulliparous women with a new LNG-IUS [J]. Gynecological Endocrinology, 2017, 33 (3):233. [17]陈雁鸣,冯颖,李长东,等.剖宫产瘢痕妊娠术后避孕方式的临床效果观察 [J].中国计划生育学杂志,2016,24(4):279-280. [18]DOKRAS A. Noncontraceptive use of oral combined hormonal contraceptives in polycystic ovary syndrome-risks versus benefits [J]. Fertility and Sterility, 2016, 106(7): 1572-1579. [19]Yang YM,Choi EJ. Efficacy and safety of metformin or oral contraceptives, or both in polycystic ovary syndrome [J]. Ther Clin Risk Manag,2015,1(11):1345-1353. [20]Yang YM, Choi EJ. Efficacy and safety of metformin or oral contraceptives, or both in polycystic ovary syndrome [J]. Ther Clin Risk Manag. 2015,1(11):1345-1353. [21]TEPPER N K, WHITEMAN M K, ZAPATA L B, et al. Safety of hormonal contraceptives among women with migraine: A systematic review [J]. Contraception, 2016, 94(6): 630-640. [22]LOPEZ L M, BERNHOLC A, CHEN M, et al. Hormonal contraceptives for contraception in overweight or obese women [J]. Obstetrics & Gynecology, 2017,116(5):1206-1207.

更新日期/Last Update: 2017-06-25